Quantcast

Latest diabetic neuropathy Stories

2008-08-12 09:01:36

Immunosyn Corporation (OTCBB:IMYN) announced today that marketing, distribution and patient treatment approval has been granted by the Ministry of Health Malaysia for SF-1019 in the Private Pay Heath Sector in Malaysia. The marketing name for SF-1019 in Malaysia will be R-1818. Argyll Biotechnologies, LLC, the licensor of SF-1019, Immunosyn's strategic partner and its largest shareholder, has notified Immunosyn that the Ministry of Health Malaysia has approved the importation, marketing...

2008-08-07 15:01:00

The Stanford University Center on Longevity and the U.S. Department of Veterans Affairs Palo Alto Health Care System (VAPAHCS) today announced positive data from their 10-week study of the Cyclic Variations in Altitude Conditioning(TM) (CVAC(TM)) process, CVAC Systems Inc.'s new modality being researched for insulin resistance and diabetes. The blinded, controlled clinical trial, which exposed subjects to the CVAC process for 40 minutes, three times a week for 10 weeks, found that the...

2008-08-05 09:01:32

SAN MATEO, Calif., Aug. 5 /PRNewswire-FirstCall/ -- NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will report results for its second quarter 2008 on Wednesday, August 13, 2008, after the market closes. A conference call to review the results will begin at 4:30 p.m. ET (1:30 p.m. PT) on August 13, 2008 and will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen...

2008-07-23 18:00:53

RICHMOND, Calif., July 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. today reported second quarter 2008 financial results and accomplishments. For the second quarter ended June 30, 2008, Sangamo reported a consolidated net loss of $7.4 million, or $0.18 per share, compared to a net loss of $5.2 million, or $0.15 per share, for the same period in 2007. As of June 30, 2008, the company had cash, cash equivalents and investments of $64.3 million. Revenues for the second quarter of...

2008-07-01 09:01:12

XTL Biopharmaceuticals has completed patient randomization into its Phase IIb study of Bicifadine - a serotonin and norepinephrine reuptake inhibitor - for the treatment of diabetic neuropathic pain. Approximately 350 patients were randomized into the study. Based on the completion of randomization, the company expects to have the last patient complete the study in the next four months. The Phase IIb trial is aimed at demonstrating the efficacy of Bicifadine in diabetic neuropathic pain,...

2008-06-18 03:00:08

By Napoli, Maryann Many people with diabetes suffer from a painful condition called peripheral neuropathy. The burning, numbness, tingling and throbbing sensations that primarily affect the feet are notoriously resistant to successful treatment. Two Australian research scientists have conducted a preliminary study showing that high doses of vitamin D may reduce these symptoms. It was published recently as a research letter in the Archives of Internal Medicine. Drs. Paul Lee and Roger Chen...

2008-01-26 06:00:10

By Papanas, N Symeonidis, G; Mavridis, G; Georgiadis, G S; Papas, T T; Lazarides, M K; Maltezos, E Aim. The aim of this study was to investigate the potential role of ankle-brachial index (ABI) as a marker of microvascular disease in patients with type 2 diabetes mellitus. Methods. This study included 126 type 2 diabetic patients (64 male and 62 female) with an age of 66.6+-5.3 years (mean+-SD) and diabetes duration of 13.2+- 4.1 years. ABI was measured with a Doppler device. The exclusion...

2006-08-18 14:25:07

NEW YORK (Reuters Health) - In more cases than would normally be expected, people who develop type 2 diabetes have a history of carpal tunnel syndrome. The wrist nerve problem sometimes predates the onset of diabetes by up to 10 years, according to a UK study. Led by Dr. Martin C. Gulliford, a team at King's College in London examined medical records for 644,495 patients in England and Wales. They identified 2647 patients diagnosed with diabetes between November 2003 and October...

2006-04-11 11:22:30

By Karla Gale SAN DIEGO (Reuters Health) - Injections of botulinum toxin A relieve pain in an animal model of diabetic neuropathy, according to research reported at the American Academy of Neurology's annual meeting in San Diego. Diabetic neuropathy is a term used for the nerve damage that occurs in people with diabetes and that often leads to pain, numbness, or tingling in the feet and hands. Five days after scientists injected the paw pad of rats with diabetic neuropathy with...

2006-02-13 11:47:13

NEW YORK (Reuters Health) - Several years after participating in a clinical trial of intensive diabetes therapy, patients assigned this treatment still showed improvements in neuropathy symptoms, according to a report Diabetes Care. The study involved 1,257 subjects who were enrolled in the Diabetes Control and Complications Trial who were randomly assigned to receive intensive or conventional diabetes therapy. The intensive approach involved at least three injections of insulin per...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'